PERCEPTIVE ADVISORS LLC
Follow13F filer, CIK 1224962, NEW YORK, NY
PERCEPTIVE ADVISORS LLC reported $5,740,273,309 across 108 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 52.05% of the portfolio.
Accepted , ingested 13F-HR 0001012975-26-001063
- Period
- 2026-09-30
- Reported value
- $5.74B
- Holdings
- 108
- Top 10 weight
- 52.05%
- New
- 26
- Sold out
- 27
Part of the filer group PERCEPTIVE ADVISORS LLC
Perceptive Credit Holdings II, L.P.EDELMAN JOSEPH
- Perceptive Credit Holdings II, L.P.
- EDELMAN JOSEPH
- Perceptive Capital Solutions Holdings LP
- Perceptive Credit Advisors LLC
- Perceptive Credit Holdings III, L.P.
- PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
- Perceptive Xontogeny Venture Fund II, LP
Stakes and trades reported after 2026-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- TRIB TRINITY BIOTECH INVT LTD: 13D/A 54,148,590 shares, 9.99% of the class, 13D/A filed 2026-11-10, 0001193125-26-455946Timeline
Accepted , ingested - IRLA QUINCE THERAPEUTICS INC: 13G 912,853 shares, 8.4% of the class, 13G filed 2026-10-14, 0001193125-26-421651Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| FRNMnew | +12,606,053 | $199M |
| AMLXadded | +2,238,853 | $65.2M |
| WATnew | +135,000 | $59.3M |
| IRDnew | +9,000,000 | $43.6M |
| LKFTnew | +1,242,404 | $36.8M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| NUVLexited | -1,580,505 | -$195M |
| APGEexited | -1,308,113 | -$174M |
| SYREreduced | -1,038,553 | -$92.5M |
| ROIVreduced | -1,574,500 | -$57.6M |
| BIIBreduced | -248,143 | -$56.1M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001012975-26-001063, largest first. % of portfolio is the value over $5,340,357,540, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| PRAXPRAXIS PRECISION MEDICINES I | 2,024,781 | $590M | 11.04% | -11,205 | Timeline | ||
| AMLXAMYLYX PHARMACEUTICALS INC | 10,573,735 | $308M | 5.76% | +2,238,853 | Timeline | ||
| SYRESPYRE THERAPEUTICS INC | 3,280,943 | $292M | 5.47% | -1,038,553 | Timeline | ||
| CELCCELCUITY INC | 3,179,794 | $253M | 4.73% | -17,406 | Timeline | ||
| RYTMRHYTHM PHARMACEUTICALS INC | 2,532,556 | $241M | 4.52% | -53,739 | Timeline | ||
| ROIVROIVANT SCIENCES LTD | 6,510,961 | $238M | 4.46% | -1,574,500 | Timeline | ||
| RLAYRELAY THERAPEUTICS INC | 12,730,336 | $230M | 4.3% | -1,375,851 | Timeline | ||
| ASNDASCENDIS PHARMA A/S | 971,521 | $221M | 4.14% | -192,200 | Timeline | ||
| TVTXTRAVERE THERAPEUTICS INC | 3,542,913 | $209M | 3.91% | -209,661 | Timeline | ||
| FRNMFREENOME INC | 12,606,053 | $199M | 3.72% | new | Timeline | ||
| EWTXEDGEWISE THERAPEUTICS INC | 4,138,282 | $168M | 3.15% | -235,692 | Timeline | ||
| INBXINHIBRX BIOSCIENCES INC | 1,292,463 | $129M | 2.42% | -5,300 | Timeline | ||
| NRIXNURIX THERAPEUTICS INC | 5,371,629 | $127M | 2.38% | +1,051,207 | Timeline | ||
| KARDKARDIGAN INC | 8,200,662 | $121M | 2.27% | 0 | Timeline | ||
| MGTXMEIRAGTX HLDGS PLC | 10,786,658 | $119M | 2.22% | 0 | Timeline | ||
| PTGXPROTAGONIST THERAPEUTICS INC | 836,579 | $118M | 2.21% | -145,300 | Timeline | ||
| IMTXIMMATICS N.V | 11,246,516 | $98.7M | 1.85% | +863,060 | Timeline | ||
| ZYMEZYMEWORKS INC | 3,545,501 | $93.9M | 1.76% | -637,452 | Timeline | ||
| ORKAORUKA THERAPEUTICS INC | 1,072,363 | $89.3M | 1.67% | -272,700 | Timeline | ||
| RVMDREVOLUTION MEDICINES INC | 433,100 | $88.9M | 1.66% | -94,500 | Timeline | ||
| SLDBSOLID BIOSCIENCES INC | 11,906,646 | $86.1M | 1.61% | 0 | Timeline | ||
| BCRXBIOCRYST PHARMACEUTICALS INC | 10,301,888 | $85.8M | 1.61% | -7,000 | Timeline | ||
| AVLNAVALYN PHARMACEUTICALS INC | 2,675,296 | $76.2M | 1.43% | 0 | Timeline | ||
| TNGXTANGO THERAPEUTICS INC | 2,693,000 | $67.2M | 1.26% | -684,000 | Timeline | ||
| WATWATERS CORP | 135,000 | $59.3M | 1.11% | new | Timeline | ||
| RGENREPLIGEN CORP | 272,456 | $52.4M | 0.98% | +24,244 | Timeline | ||
| AORTARTIVION INC | 2,112,290 | $48.2M | 0.9% | +375,000 | Timeline | ||
| ANROALTO NEUROSCIENCE INC | 1,760,950 | $45M | 0.84% | +151,057 | Timeline | ||
| IRDOPUS GENETICS INC | 9,000,000 | $43.6M | 0.82% | new | Timeline | ||
| LKFTLAKEFRONT BIOTHERAPEUTICS NV | 1,242,404 | $36.8M | 0.69% | new | Timeline | ||
| ABTABBOTT LABORATORIES | 345,225 | $34.1M | 0.64% | new | Timeline | ||
| BLSMBLOSSOMHILL THERAPEUTICS INC | 1,812,193 | $33.8M | 0.63% | new | Timeline | ||
| OBIOORCHESTRA BIOMED HLDGS INC | 5,037,606 | $31.3M | 0.59% | -300 | Timeline | ||
| CRVSCORVUS PHARMACEUTICALS INC | 2,510,441 | $28.9M | 0.54% | -157,000 | Timeline | ||
| AVRANTERIS TECHNOLOGIES GLOBAL | 3,425,476 | $26.6M | 0.5% | 0 | Timeline | ||
| ANLADLAI NORTYE GROUP LTD | 1,660,502 | $26.6M | 0.5% | -132,688 | Timeline | ||
| MMEDMINIMED GROUP INC | 1,320,000 | $25.7M | 0.48% | new | Timeline | ||
| CTMXCYTOMX THERAPEUTICS INC. | 9,268,061 | $25.2M | 0.47% | -1,171,124 | Timeline | ||
| RAPPRAPPORT THERAPEUTICS INC | 724,342 | $24.3M | 0.46% | -49,000 | Timeline | ||
| SEPNSEPTERNA INC | 567,479 | $22.2M | 0.42% | new | Timeline | ||
| XFORX4 PHARMACEUTICALS INC | 7,350,491 | $21.3M | 0.4% | -583,000 | Timeline | ||
| ELVNENLIVEN THERAPEUTICS INC | 462,506 | $21.2M | 0.4% | new | Timeline | ||
| SABSSAB BIOTHERAPEUTICS INC | 6,627,501 | $21M | 0.39% | 0 | Timeline | ||
| DYNDYNE THERAPEUTICS INC | 1,265,362 | $20.4M | 0.38% | -1,423,873 | Timeline | ||
| EOLSEVOLUS INC | 2,459,285 | $19.7M | 0.37% | 0 | Timeline | ||
| YARWYARROW BIOSCIENCE INC | 813,098 | $18.3M | 0.34% | new | Timeline | ||
| IMVTIMMUNOVANT INC | 519,345 | $17.5M | 0.33% | -838,038 | Timeline | ||
| SCTXSCRIBE THERAPEUTICS INC | 920,341 | $16.9M | 0.32% | new | Timeline | ||
| NAUTNAUTILUS BIOTECHNOLOGY INC | 11,564,744 | $16.4M | 0.31% | -69,467 | 2026-10-05, 13D/A: 4,944,512 shares, 3.9% of the class, 13D/A filed 2026-11-03 | Timeline | |
| STROSUTRO BIOPHARMA INC | 970,846 | $15.6M | 0.29% | -334,000 | Timeline | ||
| SRZNSURROZEN INC | 439,685 | $14.1M | 0.26% | -64,300 | Timeline | ||
| GRALGRAIL INC | 96,911 | $13.6M | 0.25% | new | Timeline | ||
| DBVTDBV TECHNOLOGIES S A | 1,136,534 | $13.4M | 0.25% | -516,816 | Timeline | ||
| DHRDANAHER CORP DEL | 60,000 | $13.3M | 0.25% | -70,000 | Timeline | ||
| IRTCIRHYTHM HOLDINGS INC | 113,766 | $12.9M | 0.24% | -110,000 | Timeline | ||
| GHGUARDANT HEALTH INC | 70,000 | $12.5M | 0.23% | +28,673 | Timeline | ||
| IVVDINVIVYD INC | 13,762,637 | $12M | 0.22% | -4,727,999 | Timeline | ||
| ADPTADAPTIVE BIOTECHNOLOGIES COR | 412,325 | $11.9M | 0.22% | -805,000 | Timeline | ||
| MANEVERADERMICS INC | 97,000 | $11.8M | 0.22% | new | Timeline | ||
| AXGNAXOGEN INC | 280,000 | $11.7M | 0.22% | +32,688 | Timeline | ||
| PALIPALISADE BIO INC | 8,425,065 | $11.4M | 0.21% | 0 | Timeline | ||
| CBIOCRESCENT BIOPHARMA INC. | 706,942 | $10.3M | 0.19% | +500,000 | Timeline | ||
| BBNXBETA BIONICS INC | 538,159 | $10.2M | 0.19% | -294,785 | Timeline | ||
| SPTXSEAPORT THERAPEUTICS INC | 500,000 | $10.1M | 0.19% | 0 | Timeline | ||
| ENTXENTERA BIO LTD | 3,431,372 | $9.99M | 0.19% | new | Timeline | ||
| MIRMMIRUM PHARMACEUTICALS INC | 115,391 | $9.86M | 0.18% | 0 | Timeline | ||
| QUREUNIQURE NV | 402,773 | $9.73M | 0.18% | +234,773 | Timeline | ||
| XERSXERIS BIOPHARMA HOLDINGS INC | 933,671 | $8.93M | 0.17% | +466,658 | Timeline | ||
| RACDRESEARCH ALLIANCE CORP IV | 700,000 | $8.29M | 0.16% | new | Timeline | ||
| CAPRCAPRICOR THERAPEUTICS INC | 850,000 | $8.05M | 0.15% | new | Timeline | ||
| VRDNVIRIDIAN THERAPEUTICS INC | 381,452 | $7.85M | 0.15% | -200,528 | Timeline | ||
| ABVXABIVAX SA | 74,000 | $7.33M | 0.14% | 0 | Timeline | ||
| ENGNENGENE THERAPEUTICS INC | 3,482,169 | $6.96M | 0.13% | -1,340,000 | Timeline | ||
| BLLNBILLIONTOONE INC | 65,209 | $6.94M | 0.13% | -21,603 | Timeline | ||
| AGMBAGOMAB THERAPEUTICS NV | 600,000 | $6.66M | 0.12% | 0 | Timeline | ||
| LONALEONABIO INC | 1,859,322 | $6.64M | 0.12% | 0 | 2026-10-26, 13D/A: 1,889,403 shares, 19.99% of the class, 13D/A filed 2026-10-26 | Timeline | |
| BIIBBIOGEN INC | 28,030 | $6.33M | 0.12% | -248,143 | Timeline | ||
| DMRADAMORA THERAPEUTICS INC | 282,524 | $6.01M | 0.11% | new | Timeline | ||
| ADRXADARX PHARMACEUTICALS INC | 300,000 | $5.98M | 0.11% | new | Timeline | ||
| NVCTNUVECTIS PHARMA INC | 240,000 | $5.07M | 0.09% | -760,000 | Timeline | ||
| OLMAOLEMA PHARMACEUTICALS INC | 575,000 | $4.97M | 0.09% | new | Timeline | ||
| OCSOCULIS HOLDING AG | 440,827 | $4.12M | 0.08% | -368,000 | Timeline | ||
| UNHUNITEDHEALTH GROUP INC | 10,000 | $3.67M | 0.07% | -106,806 | Timeline | ||
| MOBIMOBIA MED INC | 343,654 | $3.25M | 0.06% | -180,000 | Timeline | ||
| RVMDWREVOLUTION MEDICINES INC | 250,000 | $2.86M | 0.05% | 0 | Timeline | ||
| OMOUTSET MED INC | 833,333 | $2.5M | 0.05% | 0 | Timeline | ||
| CBLLCERIBELL INC | 98,779 | $2.41M | 0.05% | new | Timeline | ||
| EDSAEDESA BIOTECH INC | 563,239 | $2.37M | 0.04% | 0 | Timeline | ||
| BRVEBRAVEHEART BIO INC | 115,000 | $2.32M | 0.04% | new | Timeline | ||
| OTLKOUTLOOK THERAPEUTICS INC | 3,139,216 | $1.8M | 0.03% | 0 | Timeline | ||
| ADGMADAGIO MED HLDGS INC | 9,876,586 | $1.51M | 0.03% | 0 | Timeline | ||
| ADMAADMA BIOLOGICS INC | 113,765 | $1.14M | 0.02% | 0 | Timeline | ||
| KPRXKIORA PHARMACEUTICALS INC | 438,471 | $1.12M | 0.02% | 0 | Timeline | ||
| MDLNMEDLINE INC | 28,000 | $972K | 0.02% | 0 | Timeline | ||
| XGNEXAGEN INC | 114,893 | $934K | 0.02% | 0 | Timeline | ||
| CNTBCONNECT BIOPHARMA HLDGS LTD | 792,696 | $872K | 0.02% | 0 | Timeline | ||
| SGMTSAGIMET BIOSCIENCES INC | 67,674 | $669K | 0.01% | new | Timeline | ||
| IBITISHARES BITCOIN TRUST ETF | 12,000 | $568K | 0.01% | new | Timeline | ||
| ENSCENSYSCE BIOSCIENCES INC | 86,666 | $36K | <0.01% | 0 | Timeline |
Options
Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).
| Security | Type | Amount | Value | Change |
|---|---|---|---|---|
| MRNAMODERNA INC COM | put | 1,400,000 | $270M | +400,000 |
| SLSSELLAS LIFE SCIENCES GROUP I COM NEW | call | 3,000,000 | $36.9M | new |
| XBISPDR SERIES TRUST S&P BIOTECH | put | 200,000 | $31.5M | -100,000 |
| SLSSELLAS LIFE SCIENCES GROUP I COM NEW | put | 2,500,000 | $30.8M | +1,000,000 |
| NAMSNEWAMSTERDAM PHARMA COMPANY COMMON STOCK | put | 600,000 | $14.6M | +100,000 |
| EYPTEYEPOINT INC Stock | put | 3,500,000 | $11.4M | +1,500,000 |
| BHVNBIOHAVEN LTD COM | put | 200,000 | $2.67M | new |
| EYPTEYEPOINT INC Stock | call | 724,700 | $2.37M | new |
Principal amounts
Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).
| Security | Type | Amount | Value | Change |
|---|---|---|---|---|
| CELCUITY INCCELCUITY INC NOTE 2.750% 8/0 | principal | 6,500,000 | $11.7M | 0 |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| NUVLNUVALENT INC | 1,580,505 | $195M | shares |
| APGEAPOGEE THERAPEUTICS INC | 1,308,113 | $174M | shares |
| IONSIONIS PHARMACEUTICALS INC | 566,000 | $44.9M | shares |
| JAZZJAZZ PHARMACEUTICALS PLC | 170,000 | $41M | shares |
| SIONSIONNA THERAPEUTICS INC | 905,000 | $39.8M | shares |
| CORTCORCEPT THERAPEUTICS INC | 398,385 | $34.6M | shares |
| DMRADAMORA THERAPEUTICS INC | 1,223,000 | $31.8M | shares |
| CRLCHARLES RIV LABS INTL INC | 140,000 | $31.8M | shares |
| AXSMAXSOME THERAPEUTICS INC. | 118,450 | $29M | shares |
| TENXTENAX THERAPEUTICS INC | 1,700,000 | $24.7M | shares |
| CAPRCAPRICOR THERAPEUTICS INC | 1,000,000 | $24.1M | call |
| ISRGINTUITIVE SURGICAL INC | 51,884 | $20.6M | shares |
| CTNMCONTINEUM THERAPEUTICS INC | 1,255,592 | $20.6M | shares |
| OMDAOMADA HEALTH INC | 786,330 | $17.3M | shares |
| CAPRCAPRICOR THERAPEUTICS INC | 500,000 | $12M | put |
| OSCROSCAR HEALTH INC | 400,000 | $11.4M | shares |
| BSXBOSTON SCIENTIFIC CORP | 250,000 | $10.7M | shares |
| NTRANATERA INC | 34,689 | $9.42M | shares |
| RACCRESEARCH ALLIANCE CORP III | 750,000 | $8.03M | shares |
| CGEMCULLINAN THERAPEUTICS INC | 426,478 | $7.77M | shares |
| PHATPHATHOM PHARMACEUTICALS INC | 532,000 | $5.77M | shares |
| COGTCOGENT BIOSCIENCES INC | 121,082 | $4.69M | shares |
| AVTXAVALO THERAPEUTICS INC | 219,813 | $4.06M | shares |
| TWSTTWIST BIOSCIENCE CORP | 36,812 | $3.79M | shares |
| BDSXBIODESIX INC | 108,694 | $2.45M | shares |
| CPIXCUMBERLAND PHARMACEUTICALS I | 96,982 | $628K | shares |
| SRZNWSURROZEN INC | 166,666 | $2.75K | shares |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001012975-26-001063 | base | 2026-11-16 |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13G/A 0001193125-26-463818 | YARW | 2026-11-16 | ||
| 13G/A 0001193125-26-463816 | STRO | 2026-11-16 | ||
| 13G/A 0001193125-26-463815 | RACD | 2026-11-16 | ||
| 13G/A 0001193125-26-463814 | RACC | 2026-11-16 | ||
| 13G/A 0001193125-26-463813 | OBIO | 2026-11-16 | ||
| 13G/A 0001193125-26-463812 | NRIX | 2026-11-16 | ||
| 13G/A 0001193125-26-463811 | IVVD | 2026-11-16 | ||
| 13G/A 0001193125-26-463810 | IRD | 2026-11-16 | ||
| 13G/A 0001193125-26-463807 | FRNM | 2026-11-16 | ||
| 13G/A 0001193125-26-463806 | ENGN | 2026-11-16 | ||
| 13G/A 0001193125-26-463804 | EDSA | 2026-11-16 | ||
| 13G/A 0001193125-26-463803 | AMLX | 2026-11-16 | ||
| 13G/A 0001193125-26-463801 | ADGM | 2026-11-16 | ||
| 13F-HR 0001012975-26-001063 | Quarter ended 2026-09-30 | 2026-11-16 | ||
| 13D/A 0001193125-26-455946 | TRIB | 2026-11-10 | ||
| 13D/A 0001193125-26-445289 | NAUT | 2026-11-03 | ||
| Form 4 0001193125-26-431896 | LeonaBio, Inc. | 2026-10-26 | ||
| 13D/A 0001193125-26-431897 | LONA | 2026-10-26 | ||
| 13G 0001193125-26-421651 | IRLA | 2026-10-14 | ||
| 13D/A 0001193125-26-410754 | KARD | 2026-10-01 | ||
| 13F-HR 0001012975-26-000777 | Quarter ended 2026-06-30 | 2026-08-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-26-000499 | Quarter ended 2026-03-31 | 2026-05-29 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-26-000443 | Quarter ended 2026-03-31 | 2026-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-26-000155 | Quarter ended 2025-12-31 | 2026-02-17 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-25-000762 | Quarter ended 2025-09-30 | 2025-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-25-000446 | Quarter ended 2025-06-30 | 2025-08-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-25-000422 | Quarter ended 2025-03-31 | 2025-08-06 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-25-000242 | Quarter ended 2025-03-31 | 2025-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-25-000090 | Quarter ended 2024-12-31 | 2025-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-24-000488 | Quarter ended 2024-09-30 | 2024-11-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-24-000346 | Quarter ended 2024-06-30 | 2024-08-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-24-000329 | Quarter ended 2024-06-30 | 2024-08-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-24-000315 | Quarter ended 2024-03-31 | 2024-08-06 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-24-000218 | Quarter ended 2024-03-31 | 2024-05-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-24-000112 | Quarter ended 2023-12-31 | 2024-02-26 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-24-000093 | Quarter ended 2023-12-31 | 2024-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-23-000471 | Quarter ended 2023-09-30 | 2023-11-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-23-000365 | Quarter ended 2023-06-30 | 2023-08-24 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-23-000344 | Quarter ended 2023-06-30 | 2023-08-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-23-000242 | Quarter ended 2023-03-31 | 2023-05-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-23-000235 | Quarter ended 2023-03-31 | 2023-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-23-000099 | Quarter ended 2022-12-31 | 2023-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-22-000502 | Quarter ended 2022-09-30 | 2022-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-22-000365 | Quarter ended 2022-06-30 | 2022-08-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-22-000241 | Quarter ended 2022-03-31 | 2022-05-16 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-22-000209 | Quarter ended 2021-12-31 | 2022-05-04 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-22-000160 | Quarter ended 2021-12-31 | 2022-04-13 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-22-000081 | Quarter ended 2021-12-31 | 2022-02-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-21-000492 | Quarter ended 2021-09-30 | 2021-12-03 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-21-000466 | Quarter ended 2021-09-30 | 2021-11-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-21-000326 | Quarter ended 2021-06-30 | 2021-08-17 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-21-000320 | Quarter ended 2021-06-30 | 2021-08-16 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-21-000299 | Quarter ended 2021-03-31 | 2021-08-13 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-21-000242 | Quarter ended 2021-03-31 | 2021-06-10 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-21-000229 | Quarter ended 2021-03-31 | 2021-05-17 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-21-000086 | Quarter ended 2020-12-31 | 2021-02-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-20-000835 | Quarter ended 2020-09-30 | 2020-11-16 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-20-000701 | Quarter ended 2020-06-30 | 2020-08-17 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-20-000692 | Quarter ended 2020-06-30 | 2020-08-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-20-000472 | Quarter ended 2020-03-31 | 2020-05-18 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-20-000465 | Quarter ended 2020-03-31 | 2020-05-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-20-000250 | Quarter ended 2019-12-31 | 2020-02-19 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-20-000144 | Quarter ended 2019-12-31 | 2020-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-19-000707 | Quarter ended 2019-09-30 | 2019-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-19-000583 | Quarter ended 2019-06-30 | 2019-08-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-19-000380 | Quarter ended 2019-03-31 | 2019-05-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-19-000378 | Quarter ended 2019-03-31 | 2019-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-19-000177 | Quarter ended 2018-12-31 | 2019-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-18-001239 | Quarter ended 2018-09-30 | 2018-11-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-18-001190 | Quarter ended 2018-06-30 | 2018-11-01 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-18-001030 | Quarter ended 2018-06-30 | 2018-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-18-000425 | Quarter ended 2018-03-31 | 2018-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-18-000171 | Quarter ended 2017-12-31 | 2018-02-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001012975-17-000846 | Quarter ended 2017-09-30 | 2017-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-17-000831 | Quarter ended 2017-09-30 | 2017-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001012975-17-000624 | Quarter ended 2017-06-30 | 2017-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-17-000467 | Quarter ended 2017-03-31 | 2017-05-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001019056-17-000406 | Quarter ended 2016-12-31 | 2017-05-02 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001019056-17-000309 | Quarter ended 2016-12-31 | 2017-03-20 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001019056-17-000280 | Quarter ended 2016-12-31 | 2017-03-09 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-17-000196 | Quarter ended 2016-12-31 | 2017-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-16-001648 | Quarter ended 2016-09-30 | 2016-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-16-001477 | Quarter ended 2016-06-30 | 2016-08-11 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-16-001336 | Quarter ended 2016-03-31 | 2016-05-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-16-001109 | Quarter ended 2015-12-31 | 2016-02-16 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001019056-15-000911 | Quarter ended 2015-09-30 | 2015-11-17 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-15-000908 | Quarter ended 2015-09-30 | 2015-11-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-15-000685 | Quarter ended 2015-06-30 | 2015-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-15-000506 | Quarter ended 2015-03-31 | 2015-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-15-000222 | Quarter ended 2014-12-31 | 2015-02-17 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001019056-14-001423 | Quarter ended 2014-09-30 | 2014-11-17 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001019056-14-001426 | Quarter ended 2014-09-30 | 2014-11-17 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-14-001417 | Quarter ended 2014-09-30 | 2014-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-14-001053 | Quarter ended 2014-06-30 | 2014-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-14-000699 | Quarter ended 2014-03-31 | 2014-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-14-000254 | Quarter ended 2013-12-31 | 2014-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001019056-13-001282 | Quarter ended 2013-09-30 | 2013-11-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001019056-13-001286 | Quarter ended 2013-09-30 | 2013-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0000909012-13-000340 | Quarter ended 2013-06-30 | 2013-08-14 | acceptance time not in the bulk data set |